您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Sulfamethoxazole-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sulfamethoxazole-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sulfamethoxazole-d4图片
规格:98%
分子量:257.3
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
Sulfamethoxazole D4 (Ro 4-2130 D4) 是一种氘标记的磺胺甲恶唑 (Ro 4-2130)。
货号:ajcx19974
CAS:1020719-86-1
分子式:C10H7D4N3O3S
分子量:257.3
溶解度:DMSO: slightly soluble,Methanol: slightly soluble
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Sulfamethoxazole-d4 is intended for use as an internal standard for the quantification of sulfamethoxazole by GC- or LC-MS. Sulfamethoxazole is a sulfonamide antibiotic.1 It inhibits growth of E. coli (MIC = 10 μg/ml) and clinical isolates of methicillin-resistant S. aureus (MRSA; MICs = 25-50 μg/ml).2,3 Sulfamethoxazole, in combination with trimethoprim at a ratio of 20:1, inhibits growth of MRSA in vivo in mice (MIC = 0.8 μg/ml; ED50s = 6.4 and 9.6 mg/kg for two MRSA strains).3 In a mouse model of urinary tract infection with E. coli, a combination of sulfamethoxazole and trimethoprim decreases recurrent infection when administered for 10 days.4 Sulfamethoxazole acts by inhibiting dihydropteroate synthase (DHPS), which converts pteridine and 4-aminobenzoic acid to dihydropteroate, an intermediate in folate biosynthesis. It inhibits recombinant P. carinii DHPS (IC50 = 23 nM; Ki = 7.5 nM) and folate biosynthesis in situ by 48.6%. Formulations containing sulfamethoxazole and trimethoprim have been used to treat bronchitis, prostatitis, and urinary tract infections among other infectious conditions.


|1. Hong, Y.-L., Hossler, P.A., Calhoun, D.H., et al. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob. Agents Chemother. 39(8), 1756-1763 (1995).|2. Greenwood, D., and O'Grady, F. Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli. J. Clin. Pathol. 29(2), 162-166 (1976).|3. Elwell, L.P., Wilson, H.R., Knick, V.B., et al. In vitro and in vivo efficacy of the combination trimethoprim-sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 29(6), 1092-1094 (1986).|4. Schilling, J.D., Lorenz, R.G., and Hultgren, S.J. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70(12), 7042-7049 (2002).